iPSC-derived NK cell therapies are advancing rapidly with 12+ companies developing 15+ pipeline drugs. Japan's PMDA approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025. Key clinical milestones include Century Therapeutics' CNTY-101 continuing in a Phase I/II trial.
Two studies show liquid biopsy can predict immunotherapy response in HER2-negative breast cancer and identify which patients with relapsed germ cell tumors may benefit from high-dose chemotherapy, advancing precision oncology.
New research demonstrates blood-based biomarkers can predict testicular cancer recurrence and treatment outcomes, while separate study reveals long-term health risks vary by chemotherapy regimen in survivors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05092451 |
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances |
RECRUITING | PHASE1/PHASE2 |
| NCT01873326 |
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors |
ACTIVE_NOT_RECRUITING | PHASE2 |
